E. Rowinsky

发表

The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer

M. Mita, A. Mita, E. Rowinsky, 2003, Cancer biology & therapy.

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

L. Grochow, C. Hendricks, R. Donehower, 1992, Cancer research.

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

M. Beeram, E. Rowinsky, L. Hammond, 2007, Clinical Cancer Research.

Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer

C. Takimoto, S. Baker, A. Mita, 2006, Clinical Cancer Research.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Christopher U. Jones, K. Ang, P. Harari, 2006, The New England journal of medicine.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Jordi Giralt, Christopher U. Jones, K Kian Ang, 2010, The Lancet. Oncology.

A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction.

R. DeJager, C. Takimoto, P. LoRusso, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A remedy for biomarker addiction: back to rational anticancer drug development

E. Rowinsky, H. Youssoufian, 2007, Nature Clinical Practice Oncology.

The effects of food and divided dosing on the bioavailability of oral vinorelbine

R. Donehower, E. Rowinsky, B. Lubejko, 1996, Cancer Chemotherapy and Pharmacology.

The current status of camptothecin analogues as antitumor agents.

E K Rowinsky, S H Kaufmann, R. Donehower, 1993, Journal of the National Cancer Institute.

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.

R. Donehower, E. Rowinsky, 1991, Pharmacology & therapeutics.

Phase II Study of 4-Ipomeanol, a Naturally Occurring Alkylating Furan, in Patients with Advanced Hepatocellular Carcinoma

R. Donehower, E. Rowinsky, S. Lakhanpal, 2004, Investigational New Drugs.

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.

M. Hidalgo, G. Weiss, H. Rosing, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Population pharmacokinetic model for topotecan derived from phase I clinical trials.

L. Grochow, S. Baker, E. Rowinsky, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

E K Rowinsky, L. Grochow, D. Ettinger, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.

R. Ozols, J. Walczak, R. Alvarez, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.

G. Weiss, D. V. Von Hoff, H. Burris, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?

A. Tolcher, C. Takimoto, E. Rowinsky, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early Clinical Experience with Farnesyl Protein Transferase Inhibitors

A. Patnaik, E. Rowinsky, 2001 .

The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases

A. Patnaik, E. Rowinsky, 2000 .

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

A. Tolcher, C. Takimoto, E. Rowinsky, 2005, Clinical Cancer Research.

Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors

D. Mould, J. Schellens, H. Rosing, 2002, Clinical pharmacology and therapeutics.

Paclitaxel in cancer treatment

E. Rowinsky, W. Mcguire, 1995 .

Phase I trial of taxol in patients with advanced cancer.

L. Grochow, D. Ettinger, R. Donehower, 1987, Cancer treatment reports.

Successful re-treatment with taxol after major hypersensitivity reactions.

M. Piccart, E. Eisenhauer, L. Gianni, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer

H. Wakelee, D. Dunlop, R. Ramlau, 2012, Cancer Chemotherapy and Pharmacology.

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

L. Grochow, J. Verweij, J. Schellens, 2002, Journal of the National Cancer Institute.

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

L. Grochow, D. Ettinger, R. Donehower, 1994, Cancer research.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.

S. Piantadosi, S. Grossman, E. Rowinsky, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

R. Donehower, E. Rowinsky, R. Tucker, 1988, Cancer research.

Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells.

R. Donehower, E. Rowinsky, D. Allison, 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Development of polyploidization in taxol-resistant human leukemia cells in vitro.

R. Donehower, E. Rowinsky, D. Allison, 1990, Cancer research.

Taxol: the first of the taxanes, an important new class of antitumor agents.

S. Arbuck, N. Onetto, E. Rowinsky, 1992, Seminars in oncology.

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

L. Grochow, R. Donehower, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms

G. Weiss, D. V. Von Hoff, L. Smith, 2004, Clinical Cancer Research.

Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.

G. Weiss, D. V. Von Hoff, S. Baker, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacokinetic S tudy o f T emozolomide on a D aily-for-5-Days S chedule i n P atients With A dvanced S olid M alignancies

G. Weiss, S. Baker, D. V. Hoff, 1999 .

Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.

L. Grochow, R. Donehower, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

A. Tolcher, I. Thompson, L. Smetzer, 2004, Clinical Cancer Research.

Novel agents that target tublin and related elements.

E. Rowinsky, E. Calvo, 2006, Seminars in oncology.

Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies

R. Figlin, A. Belldegrun, J. Crawford, 2005 .

Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 2000, European journal of cancer.

Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.

D. Ludwig, E. Rowinsky, F. Fox, 2011, Current drug targets.

mline Polymorphisms in Genes Involved in the IGF 1 hway Predict Efficacy of Cetuximab in Wild-type R S mCRC Patients

H. Lenz, A. Gerger, P. Wilson, 2010 .

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

M. Moore, E. Rowinsky, D. Jonker, 2011, Investigational New Drugs.

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

D. Ettinger, R. Donehower, E. Rowinsky, 1989 .

Erosion of the principal investigator role in a climate of industry dominance.

E. Rowinsky, 2005, European journal of cancer.

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.

A. Tolcher, E. Rowinsky, J. D. de Bono, 2003, Seminars in oncology.

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.

G. Weiss, D. V. Von Hoff, S. Hilsenbeck, 1998, Blood.

Therapeutics targeting signal transduction for patients with colorectal carcinoma.

E. Rowinsky, J. D. de Bono, 2002, British medical bulletin.

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

A. Wolff, J. Verweij, S. Baker, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.

L. Grochow, R. Donehower, E. Rowinsky, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Clinical experience with monoclonal antibodies to epidermal growth factor receptor

E. Rowinsky, E. Calvo, 2005, Current oncology reports.

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

L. Denis, A. DeCillis, E. Rowinsky, 2004, Clinical Cancer Research.

APhase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

M. Beeram, E. Rowinsky, L. Hammond, 2007 .

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.

R. Figlin, A. Belldegrun, J. Crawford, 2004, International journal of radiation oncology, biology, physics.

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay

D. V. Von Hoff, S. Hilsenbeck, C. Britten, 1999, Cancer Chemotherapy and Pharmacology.

A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (mCRC)

M. Moore, E. Rowinsky, D. Jonker, 2008 .

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

A. Tolcher, C. Takimoto, A. Patnaik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

L. Grochow, D. Ettinger, R. Donehower, 2004, Cancer Chemotherapy and Pharmacology.

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

E. Rowinsky, S. O'reilly, Seamus O'Reilly, 1996, Critical reviews in oncology/hematology.

A phase II trial of topotecan in patients with previously untreated pancreatic cancer

L. Grochow, R. Donehower, E. Rowinsky, 1996, Anti-cancer drugs.

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

L. Grochow, D. Ettinger, R. Donehower, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies

A. Tolcher, C. Takimoto, F. Giles, 2011, Clinical Cancer Research.

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

C. Takimoto, S. Mani, M. Mita, 2009, Clinical Cancer Research.

A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors

A. Tolcher, A. Lockhart, E. Rowinsky, 2009, American journal of clinical oncology.

Spontaneous pneumothorax following thoracic irradiation.

E. Rowinsky, M. Wharam, M. Abeloff, 1985, Chest.

UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer.

E. Rowinsky, 1999 .

Novel radiation sensitizers targeting tissue hypoxia.

E. Rowinsky, 1999, Oncology.

A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)

H. Wakelee, C. Takimoto, E. Rowinsky, 2012, Cancer Chemotherapy and Pharmacology.

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

S. Tavazoie, Shugaku Takeda, A. Ribas, 2018, Cell.

A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.

K., M. Hidalgo, G. Weiss, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

M. Hidalgo, M. Moore, S. Baker, 2006, Clinical Cancer Research.

Curtailing the High Rate of Late-Stage Attrition of Investigational Therapeutics Against Unprecedented Targets in Patients with Lung and Other Malignancies

E. Rowinsky, 2004, Clinical Cancer Research.

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy

J. Rigas, R. Perez-soler, G. Clark, 2003 .

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

A. Tolcher, C. Takimoto, M. Beeram, 2007, Clinical Cancer Research.

Metastatic Cancer Supplementation in Patients with Locally Advanced or High-Dose Folic Acid Supplementation or Multivitamin Phase I and Pharmacokinetic Study of Pemetrexed with

A. Tolcher, C. Takimoto, M. Beeram, 2007 .

Novel Agents in the Treatment of Lung Cancer

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical Cancer Research.

A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.

C. Takimoto, A. Patnaik, E. Rowinsky, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

A. Tolcher, C. Takimoto, D. V. Von Hoff, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The new generation of targeted therapies for breast cancer.

E. Rowinsky, S. Syed, 2003, Oncology.

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea

G. Weiss, S. Hilsenbeck, D. V. Hoff, 1998 .

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPYAGENTS

E. Rowinsky, 1997 .

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

R. Ozols, P. O'dwyer, S. Johnson, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.

A. Tolcher, C. Takimoto, L. Smith, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical pharmacology of Taxol.

E. Rowinsky, 1993, Journal of the National Cancer Institute. Monographs.

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.

R. Elledge, D. V. Von Hoff, M. Villalona-Calero, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study

S. Grossman, G. Lesser, E. Rowinsky, 2004, Cancer Chemotherapy and Pharmacology.

Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia

R. Donehower, E. Rowinsky, W. Mcguire, 1995, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

A. Tolcher, C. Geyer, C. Takimoto, 2009, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.

M. Hidalgo, G. Weiss, D. V. Von Hoff, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

648 POSTER A phase I dose-escalation study of weekly IMC-A12, a fully human insulin like growth factor-I receptor (IGF-IR) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

C. Higano, P. LoRusso, E. Rowinsky, 2006 .

Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

D. Ettinger, R. Donehower, J. Karp, 1989, Cancer research.

Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.

M. Hidalgo, D. V. Von Hoff, A. Patnaik, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A widening prospect: Imatinib and novel applications of targeted therapy.

E. Rowinsky, 2004, Seminars in oncology.

A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.

D. V. Von Hoff, L. Smetzer, H. Burris, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of 1843 U 89 , a Noncompetitive Inhibitor of Thymidylate Synthase , in Patients with Advanced Solid Malignancies 1

L. Smetzer, H. Burris, D. V. Hoff, 2001 .

Targeting the target of rapamycin (TOR): looking to mother nature

E. Rowinsky, 2011, Targeted Oncology.

A reassessment of cardiac toxicity associated with Taxol.

M. Christian, H. Gibbs, S. Arbuck, 1993, Journal of the National Cancer Institute. Monographs.

Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes".

E. Rowinsky, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Population P harmacokinetic M odel f or T opotecan D erived From P hase I C linical T rials

L. Grochow, S. Baker, E. Rowinsky, 2000 .

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.

M. Hidalgo, G. Weiss, C. Britten, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

M. Hidalgo, L. Smith, E. Rowinsky, 2001 .

Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.

B. Murphy, E. Rowinsky, G. Adams, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Squalamine , an Aminosterol Angiogenesis Inhibitor 1

A. Tolcher, C. Takimoto, A. Patnaik, 2003 .

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

R. Barakat, S. Rubin, J. Lewis, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The taxanes: dosing and scheduling considerations.

E. Rowinsky, 1997, Oncology.

Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days.

G. Wilding, E. Rowinsky, Q. Chu, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Camptothecin analogues: studies from The Johns Hopkins Oncology Center

L. Grochow, R. Donehower, W. Slichenmyer, 2004, Cancer Chemotherapy and Pharmacology.

Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

E. Rowinsky, 2002, The oncologist.

A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.

M. Grever, M. Borowitz, R. Donehower, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

L. Grochow, R. Donehower, S. Kaufmann, 1992, Drug metabolism and disposition: the biological fate of chemicals.

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

D. Ludwig, E. Rowinsky, H. Youssoufian, 2007, Clinical Cancer Research.

IMC-A 12 , a Human IgG 1 Monoclonal Antibody to the Insulin-Like Growth Factor IReceptor

D. Ludwig, E. Rowinsky, D. Burtrum, 2007 .

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

J. Buckner, M. Hidalgo, A. Berkenblit, 2010, Investigational New Drugs.

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

P. Bonate, G. Weiss, A. Mita, 2006, Clinical Cancer Research.

Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors

P. Bonate, A. Mita, E. Rowinsky, 2006 .

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

A. Tolcher, C. Takimoto, A. Patnaik, 2004, Clinical Cancer Research.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

G. Rosner, M. Ratain, K. Flaherty, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot Trial of Alternating Paclitaxel and Doxorubicin in Advanced Breast Cancer

D. Neuberg, W. McCaskill-Stevens, G. Sledge, 1997 .

Murine and human in vivo penclomedine metabolism.

E. Rowinsky, J. Strong, J. Collins, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies

R. Donehower, E. Rowinsky, D. Cornblath, 1994, Annals of neurology.

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

L. Grochow, D. Noe, S. Khor, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol: pharmacology, metabolism and clinical implications.

B. Monsarrat, R. Donehower, G. Lesser, 1993, Cancer surveys.

Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.

E. Rowinsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies

M. Thomas, J. Abbruzzese, E. Rowinsky, 2012, Investigational New Drugs.

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

L. Shulman, J. Picus, E. Rowinsky, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2008 .

EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144)

H. Lenz, H. Chang, R. Ladner, 2007 .

Preclinical and Clinical Development of Exatecan (DX-951f)

E. Rowinsky, 2005 .

AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: Preliminary phase 1 results

C. Takimoto, J. Tabernero, E. Martinelli, 2005 .

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

A. Tolcher, P. LoRusso, A. Patnaik, 2004, Clinical Cancer Research.

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

L. Grochow, R. Donehower, S. Kaufmann, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.

L. Grochow, R. Donehower, S. Baker, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

L. Grochow, R. Donehower, S. Kaufmann, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.

R. Barakat, P. Francis, J. Lewis, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

A. Tolcher, L. Denis, M. Beeram, 2009, Clinical Cancer Research.

Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFR{alpha} in patients with advanced solid malignancies

R. Amato, E. Rowinsky, E. Chiorean, 2008 .

Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.

S. Kaufmann, P. Svingen, A. Adjei, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

L. Grochow, D. Noe, R. Donehower, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.

C. Takimoto, D. V. Von Hoff, L. Smetzer, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.

D. Neuberg, W. McCaskill-Stevens, G. Sledge, 1994, Seminars in oncology.

An overview of experience with TAXOL (paclitaxel) in the U.S.A.

R. Donehower, E. Rowinsky, Ross C. Donehower, 1993, Cancer treatment reviews.

A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies

A. Tolcher, C. Takimoto, A. Patnaik, 2004, Investigational New Drugs.

Evaluation of the factors influencing the clearance of the novel thymidylate synthase inhibitor ZD9331

C. Britten, S. Baker, E. Douglass, 1999 .

A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077.

G. Weiss, D. V. Von Hoff, C. Britten, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Nifedipine and oncologic Raynaud phenomenon.

R. Donehower, E. Rowinsky, A. Hantel, 1988, Annals of internal medicine.

Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.

D. Noe, M. Zahurak, R. Donehower, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan in combination chemotherapy.

S. Kaufmann, E. Rowinsky, S H Kaufmann, 1997, Seminars in oncology.

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

M. Grever, L. Grochow, R. Donehower, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.

M. Hidalgo, D. V. Von Hoff, L. Smith, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

M. Gleave, A. Tolcher, C. Takimoto, 2005, Clinical Cancer Research.

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

P. Westervelt, J. Dipersio, L. Gorelik, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.

B. Conley, R. Donehower, E. Rowinsky, 1992, Leukemia.

PATIENTS AND METHODS

D. Neuberg, S. Martino, G. Sledge, 1982 .

Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies

C. Takimoto, C. Verschraegen, M. Mita, 2009, Cancer Chemotherapy and Pharmacology.

Cantuzumab M ertansine, a M aytansinoid I mmunoconjugate Directed t o t he C anAg A ntigen: A P hase I , P harmacokinetic, and B iologic C orrelative S tudy

A. Tolcher, C. Takimoto, L. Smith, 2003 .

Early Clinical Experience with Farnesyl Protein Transferase Inhibitors: From the Bench to the Bedside

A. Patnaik, E. Rowinsky, 2000 .

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

M. Konopleva, O. Frankfurt, F. Garnache-Ottou, 2014, Blood.

Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel

M. Beeram, R. Perez, M. Mita, 2007, Clinical Cancer Research.

Patient Care Issues: The Management of Paclitaxel-Related Toxicities

E. Rowinsky, R. Finley, 1994, The Annals of pharmacotherapy.

Tubulin-Targeting Drugs

A. Tolcher, E. Rowinsky, J. Bono, 2001 .

Taxol: twenty years later, the story unfolds.

R. Donehower, E. Rowinsky, 1991, Journal of the National Cancer Institute.

Neurotoxicity of Taxol.

R. Donehower, E. Rowinsky, D. Cornblath, 1993, Journal of the National Cancer Institute. Monographs.

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

L. Grochow, D. Ettinger, D. Noe, 1990, Cancer research.

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.

D. V. Von Hoff, G. Weiss, S. Baker, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion.

L. Grochow, R. Donehower, H. Pieniaszek, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.

S. Kaufmann, Y. Cheng, P. Svingen, 1997, Blood.

Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine

M. Citardi, D. Noe, R. Donehower, 2005, Journal of Cancer Research and Clinical Oncology.

Incorporating Assessments of Sequence-Dependence in Developmental Studies of Combination Chemotherapy Regimens Containing New Agents and Platinum Compounds

E. Rowinsky, 1996 .

411 Pharmacodynamic evaluation of the mTOR inhibitor AP23573 in phase 1 clinical trials

M. Ratain, T. Clackson, A. Tolcher, 2004 .

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies

A. Tolcher, M. Mita, C. Bedrosian, 2004 .

4 Metabolism and pharmacology of taxoids

B. Monsarrat, R. Donehower, E. Rowinsky, 1995 .

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

E. Rowinsky, G. Schwartz, J. D. de Bono, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy.

E. Rowinsky, W. Mcguire, 1991, Seminars in oncology.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

J. Rigas, R. Perez-soler, G. Clark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer

D. Ettinger, E. Rowinsky, S. Sartorius, 2004, Investigational New Drugs.

Phase I a nd P harmacologic S tudy o f O SI-774, a n Epidermal G rowth F actor R eceptor T yrosine K inase Inhibitor, i n P atients W ith A dvanced S olid M alignancies

M. Hidalgo, J. Nemunaitis, C. Takimoto, 2001 .

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units

Cesario Z. Cerna, D. V. Von Hoff, L. Siu, 2004, Investigational New Drugs.

Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.

M. Jiroutek, S. Baker, E. Rowinsky, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.

G. Weiss, D. V. Von Hoff, H. Burris, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors 1

G. Weiss, H. Burris, S. Baker, 1999 .

Pharmacokinetic profiles of doxorubicin in combination with taxanes.

F. Holmes, E. Rowinsky, 2001, Seminars in oncology.

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

P. Venugopal, P. Richardson, K. Porkka, 2020, Investigational New Drugs.

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.

M. Hidalgo, A. Tolcher, G. Weiss, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination

M. Gilbert, M. Citardi, D. Noe, 1991 .

Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.

C. Serdar, J. Gutheil, L. Rosen, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ErbB receptor family: a therapeutic target for cancer.

E. Rowinsky, J. D. de Bono, 2002, Trends in molecular medicine.

Hepatic metabolism and biliary excretion of Taxol in rats and humans.

B. Monsarrat, R. Donehower, E. Rowinsky, 1993, Journal of the National Cancer Institute. Monographs.

Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.

M. Konopleva, M. Andreeff, H. Kantarjian, 2013 .

Docetaxel in combination with fluorouracil: study design and preliminary results.

D. V. Von Hoff, P. Ravdin, H. Burris, 1997, Oncology.

Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.

L. Grochow, D. Ettinger, D. Noe, 1987, Cancer research.

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

E. Rowinsky, H. Youssoufian, J. Tonra, 2010, Cancer.

Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.

E. Lakatta, M. Crow, L. Cheng, 1995, The Journal of clinical investigation.

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

R. Figlin, K. Foon, J. Gollob, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells

C. Brooks, A. Tefferi, E. Rowinsky, 2015, Leukemia.

Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.

M. Hidalgo, L. Siu, M. Brattain, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study

A. Tolcher, C. Takimoto, M. Mita, 2005 .

166 A phase I dose-escalation study of anti-a5β1 integrin monoclonal antibody (M200) in patients with refractory solid tumors

A. Tolcher, G. Wilding, E. Rowinsky, 2004 .

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

H. Lenz, H. Chang, A. El-Khoueiry, 2008, Clinical Cancer Research.

Progress in the management of gynecologic cancer: consensus summary statement.

R. Bast, S. Skates, J. Garber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.

B. Monsarrat, R. Donehower, E. Rowinsky, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

The clinical pharmacology of paclitaxel (Taxol).

R. Donehower, E. Rowinsky, 1993, Seminars in oncology.

Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas

A. Tolcher, C. Takimoto, M. Saif, 2005, Clinical Cancer Research.

Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.

E. Rowinsky, S. O'reilly, 1997, Hematology/oncology clinics of North America.

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

L. Grochow, D. Ettinger, C. Hendricks, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies.

D. V. Von Hoff, D. Kufe, M. Villalona-Calero, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol: a novel investigational antimicrotubule agent.

R. Donehower, E. Rowinsky, L. Cazenave, 1990, Journal of the National Cancer Institute.

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

M. Kris, M. Ranson, V. Miller, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

D. Hicklin, E. Rowinsky, H. Youssoufian, 2007, Clinical Cancer Research.

Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.

L. Grochow, D. Ettinger, R. Donehower, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.

E. Rowinsky, 1997, Annual review of medicine.

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patientswith Advanced SolidTumors

A. Tolcher, C. Takimoto, E. Rowinsky, 2005 .

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

E K Rowinsky, M. Hidalgo, A. Tolcher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Massive adrenal hemorrhage secondary to metastatic lung carcinoma.

E. Rowinsky, M. Abeloff, R. Jones, 1986, Medical and pediatric oncology.

Cardiac disturbances during the administration of taxol.

E K Rowinsky, M. Christian, T. Guarnieri, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.

W. May, E. Rowinsky, S. Sharkis, 1990, Blood.

Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.

M. Hidalgo, D. V. Von Hoff, G. Weiss, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.

D. V. Von Hoff, C. Britten, S. Baker, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

C. Fuchs, P. Deutsch, Sunil Sharma, 2002, Molecular cancer therapeutics.

A Phase I and Pharmacokinetic Study of SAM 486 A , a Novel Polyamine Biosynthesis Inhibitor , Administered on a Daily-times-five every-three-week Schedule in Patients with Advanced Solid Malignancies 1

M. Hidalgo, G. Weiss, G. Clark, 2002 .

Raf: a strategic target for therapeutic development against cancer.

M. Beeram, A. Patnaik, E. Rowinsky, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug therapy : paclitaxel (Taxol)

R. Donehower, E. Rowinsky, E. K. Rowinsky, 1995 .

Paclitaxel (taxol)

E K Rowinsky, R. Donehower, E. Rowinsky, 1995, The New England journal of medicine.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

M. Ratain, K. Flaherty, I. Judson, 2011, Investigational New Drugs.

Phase I and Pharmacokinetic Study of Sequential Paclitaxel and Trabectedin Every 2 Weeks in Patients with Advanced Solid Tumors

A. Tolcher, A. Mita, E. Rowinsky, 2010, Clinical Cancer Research.

Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.

A. Tolcher, K. Papadopoulos, A. Patnaik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

M. Hidalgo, E. Rowinsky, 2000, Oncogene.

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

M. Mita, A. Mita, E. Rowinsky, 2004, Clinical colorectal cancer.

Selected Targets and Rationally Designed Therapeutics for Patients with Colorectal Cancer

E. Rowinsky, 2002 .

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.

G. Demetri, G. Gordon, E. Rowinsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel pharmacology and other tumor types.

E. Rowinsky, 1997, Seminars in oncology.

Acute retinal toxicity from the novel anti-tumor agent, Irofulven

R. Melendez, E. Rowinsky, L. Hammond, 2004, Documenta Ophthalmologica.

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

E K Rowinsky, D. V. Von Hoff, J. Windle, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

J. Buckner, M. Hidalgo, C. Erlichman, 2006, Clinical Cancer Research.

Pharmacokinetic Study ofTemsirolimus ( CCI-779 ) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

J. Buckner, M. Hidalgo, C. Erlichman, 2006 .

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

A. Tolcher, T. Mays, A. Patnaik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

E. Rowinsky, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the molecular target of rapamycin (mTOR)

E. Rowinsky, 2004, Current opinion in oncology.

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhen-ping Zhu, Yan Wu, D. Ludwig, 2010, Clinical Cancer Research.

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.

E. Rowinsky, 2004, Annual review of medicine.

Signal events: Cell signal transduction and its inhibition in cancer.

E. Rowinsky, Eric K Rowinsky, 2003, The oncologist.

Crossing the cancer cell membrane to improve clinical outcomes.

E. Rowinsky, 2003, The oncologist.

Update on the Antitumor Activity of Paclitaxel in Clinical Trials

E. Rowinsky, 1994, The Annals of pharmacotherapy.

Innovative Rational-Derived, Target-Based and Cytotoxic Therapies for Breast Cancer and Other Malignancies

E. Rowinsky, 2006 .

Clinical toxicities encountered with paclitaxel (Taxol).

E. Eisenhauer, S. Arbuck, R. Donehower, 1993, Seminars in oncology.

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.

E. Winer, D. Ettinger, D. Noe, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mammalian target of rapamycin: a new molecular target for breast cancer.

M. Mita, A. Mita, E. Rowinsky, 2003, Clinical breast cancer.

A phase I pharmacokinetic (PK) trial of XAA296A (Discodermolide) administered every 3 wks to adult patients with advanced solid malignancies.

A. Lockhart, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

H. Lenz, A. Gerger, P. Wilson, 2010, Clinical Cancer Research.

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

E. Van Cutsem, H. Lenz, Z. Tsuchihashi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

E K Rowinsky, D. V. Von Hoff, E. Rowinsky, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

M. Hidalgo, A. Tolcher, M. Beeram, 2006, Clinical Cancer Research.

Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies

D. DeAngelo, E. Rowinsky, O. Ottmann, 2005 .

Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks.

D. V. Von Hoff, H. Burris, S. Baker, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

P. Atadja, A. Tolcher, P. Workman, 2008, Clinical Cancer Research.

Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

M. Hidalgo, C. Erlichman, A. Adjei, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

F. Garnache-Ottou, C. Brooks, E. Deconinck, 2015, Haematologica.

Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.

L. Denis, C. Britten, L. Siu, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.

E. Rowinsky, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

D. Neuberg, S. Martino, G. Sledge, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.

E K Rowinsky, L. Grochow, D. Ettinger, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

M. Mita, E. Rowinsky, G. Schwartz, 2007, Investigational New Drugs.

Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors

J. Berlin, A. Tolcher, K. Papadopoulos, 2008, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of Hepsulfam ( NSC 329680 ) 1

L. Grochow, D. Ettinger, C. Hendricks, 2006 .

Phase I and pharmacokinetic study of hepsulfam (NSC 329680).

L. Grochow, D. Ettinger, C. Hendricks, 1991, Cancer research.

Phase 1 study of weekly anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody IMC-18F1 in patients with advanced solid malignancies

P. LoRusso, E. Rowinsky, F. Fox, 2008 .

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Manuel Hidalgo, M. Hidalgo, A. Tolcher, 2004, Clinical Cancer Research.

Dose-intense paclitaxel: deja vu all over again?

C. Takimoto, E. Rowinsky, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

M. Jiroutek, D. Cella, D. Fairclough, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.

E. Rowinsky, E. Calvo, 2004, Clinical lung cancer.

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

M. Kahn, H. Lenz, W. Zhang, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacologic study of topotecan in patients with impaired renal function.

L. Grochow, D. Ettinger, R. Donehower, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.

R. Donehower, S. Baker, S. Kaufmann, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.

L. Grochow, D. Ettinger, R. Donehower, 1996, Journal of the National Cancer Institute.

Vascular endothelial growth factor receptor‐1 in human cancer

Yan Wu, E. Rowinsky, H. Youssoufian, 2010, Cancer.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

D. Camidge, L. Chow, S. Leong, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.

E. Raymond, D. V. Von Hoff, G. Clark, 1997, Anti-cancer drugs.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

A. Tolcher, C. Geyer, L. Denis, 2003, British Journal of Cancer.

Targeting mTOR: A Little Bit of History and a Large Future

E. Rowinsky, 2016 .

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

J. Verweij, M. D. de Jonge, A. Mita, 2010, European journal of cancer.

Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.

E K Fishman, E K Rowinsky, D. Ettinger, 1993, Cancer research.

Handbook of Anticancer Drug Development

B. Hill, E. Rowinsky, D. Budman, 2003 .

The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum

M. Molliver, E. Rowinsky, R. Struck, 2003, Investigational New Drugs.

Tissue and tumor distribution of C-penclomedine in rats.

R. Donehower, S. Grossman, G. Lesser, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibiting Signal Transduction: Recent Advances in the Development of Receptor Tyrosine Kinase and Ras Inhibitors

E. Rowinsky, D. Hao, 2002, Cancer investigation.

Novel Anticancer Agents in Clinical Development

A. Adjei, E. Rowinsky, 2003, Cancer biology & therapy.

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma

A. Tolcher, G. Weiss, C. Takimoto, 2007, Cancer Chemotherapy and Pharmacology.

A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.

A. Tolcher, C. Takimoto, L. Denis, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Status and Optimal Use of Topotecan

E. Rowinsky, 2017 .

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

M. Hidalgo, M. Mita, A. Mita, 2009, Clinical Cancer Research.

A Risk-Benefit Assessment of Irinotecan in Solid Tumours

L. Siu, E. Rowinsky, E. Rowinsky, 1998, Drug safety.

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.

B. Reigner, H. Burger, G. Weiss, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I a nd P harmacokinetic S tudy o f t he O ral Fluoropyrimidine C apecitabine i n C ombination W ith Paclitaxel i n P atients W ith A dvanced S olid M alignancies

B. Reigner, H. Burger, G. Weiss, 1999 .

Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.

L. Grochow, D. Noe, M. Zahurak, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

mTOR Inhibition for Cancer Therapy: Past, Present and Future

M. Mita, A. Mita, E. Rowinsky, 2016 .

Phase I a nd P harmacokinetic S tudy o f L U79553, a D NA Intercalating B isnaphthalimide , i n P atients W ith S olid Malignancies

D. Kufe, M. Villalona-Calero, D. Toppmeyer, 2001 .

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

G. Giaccone, E. Voest, E. Rowinsky, 2010, Clinical Cancer Research.

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.

L. Grochow, R. Donehower, S. Kaufmann, 1996, Journal of the National Cancer Institute.

Alternative dosing schedules for irinotecan.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 1998, Oncology.

Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.

L. Grochow, R. Donehower, S. Kaufmann, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A P hase I a nd P harmacokinetic S tudy o f P egylated Camptothecin a s a 1 -Hour I nfusion E very 3 W eeks i n P atients With A dvanced S olid M alignancies

A. Tolcher, C. Takimoto, L. Denis, 2003 .

A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.

A. Tolcher, C. Geyer, C. Takimoto, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor

E. Rowinsky, E. Calvo, 2005, Current oncology reports.

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

C. Brooks, E. Rowinsky, A. Frankel, 2013 .

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.

E K Rowinsky, S G Hilsenbeck, D. V. Von Hoff, 1999, Cancer research.

DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

A. Tolcher, C. Geyer, D. V. Von Hoff, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On pushing the outer edge of the outer edge of paclitaxel's dosing envelope.

E K Rowinsky, E. Rowinsky, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hexamethylene bisacetamide-induced cutaneous vasculitis.

D. Ettinger, R. Donehower, E. Rowinsky, 1987, Cancer treatment reports.

Vinorelbine and the topoisomerase 1 inhibitors: Current and potential roles in breast cancer chemotherapy

R. Donehower, E. Rowinsky, M. J. Kennedy, 2004, Breast Cancer Research and Treatment.

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

M Markman, P. Francis, E. Rowinsky, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer

D. Noe, R. Donehower, A. Adjei, 2003, Investigational New Drugs.

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.

M. Hidalgo, G. Weiss, A. Patnaik, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study

L. Grochow, D. Ettinger, R. Donehower, 1989, Investigational New Drugs.

Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.

L. Grochow, D. Ettinger, D. Noe, 1990, Cancer research.

Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.

E K Rowinsky, L. Grochow, D. Ettinger, 1989, Journal of the National Cancer Institute.

Clinical and pharmacologic reappraisal of dichloromethotrexate.

L. Grochow, D. Ettinger, D. Noe, 1988, Journal of the National Cancer Institute.

Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.

L. Grochow, D. Ettinger, D. Noe, 1988, Journal of the National Cancer Institute.

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.

L. Grochow, R. Diasio, S. Khor, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of adriamycin (A) + taxol (T) in metastatic breast cancer (MBC)

D. Neuberg, G. Sledge, N. Robert, 1993 .

A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.

S. Soignet, P. Deutsch, C. Britten, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase II Study of Intravenous Exatecan Administered Daily for 5 Days, Every 3 Weeks to Patients With Biliary Tract Cancers

G. Abou-Alfa, G. Schwartz, Sunil Sharma, 2005, American journal of clinical oncology.

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

R. DeJager, R. Pazdur, L. Saltz, 2004, Investigational New Drugs.

Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.

D. V. Von Hoff, G. Clark, E. Rowinsky, 1999, Anti-cancer drugs.

Review of phase I clinical studies with topotecan.

J. Verweij, E. Rowinsky, 1997, Seminars in oncology.

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

A. Tolcher, E. Rowinsky, J. D. de Bono, 2003, Breast Cancer Research.

Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.

R. Donehower, Richard J. Jones, C. Griffin, 1990, Journal of the National Cancer Institute.

Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.

D. V. Von Hoff, E. Rowinsky, H. Liapis, 1999, Journal of the National Cancer Institute.

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

E. Rowinsky, H. Youssoufian, G. Shah, 2010, Cancer.

in blastic plasmacytoid dendritic cell neoplasm patients Activity of SL-401, a targeted therapy directed to interleukin-3 receptor,

M. Konopleva, O. Frankfurt, C. Brooks, 2014 .

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

K. Ang, P. Harari, J. Jassem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.

A. Tolcher, C. Takimoto, A. Patnaik, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

E. Rowinsky, L. Goldstein, Q. Chu, 2008, Clinical Cancer Research.

APhase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

E. Rowinsky, L. Goldstein, Q. Chu, 2008 .

Fully Human IgG 1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

G. Giaccone, E. Voest, E. Rowinsky, 2010 .

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

M. Hidalgo, D. V. Von Hoff, G. Clark, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors.

P. Atadja, A. Patnaik, M. Mita, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.

L. Grochow, D. Noe, R. Donehower, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

M. Ranson, E. Rowinsky, V. Alakhov, 2011, Investigational New Drugs.

The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

E. Rowinsky, 2012, Drugs.

Factors Affecting Topotecan Sensitivity in Human Leukemia Samples a

L. Grochow, R. Donehower, Richard J. Jones, 1996, Annals of the New York Academy of Sciences.

Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390)1

L. Grochow, D. Ettinger, D. Noe, 2006 .

Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids

E. Rowinsky, 1991, Current Opinion in Oncology.

Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.

D. Ettinger, E. Rowinsky, S. Sartorius, 1995, Seminars in oncology.

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2014, British journal of haematology.

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2012 .

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

A. Patnaik, D. V. Hoff, E. Rowinsky, 2007, Cancer Chemotherapy and Pharmacology.

Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?

P. Francis, E. Rowinsky, M. Markman, 1995, Seminars in oncology.

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

H. Lenz, E. Rowinsky, A. Ko, 2012, Investigational New Drugs.

Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers

H. Hurwitz, E. Rowinsky, E. Chiorean, 2007 .

Novel agents in the treatment of lung cancer: conference summary statement.

G. Giaccone, M. Socinski, G. Scagliotti, 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients

E. Rowinsky, L. Goldstein, Q. Chu, 2005 .

Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.

M. Mita, E. Rowinsky, L. Hammond, 2004, Journal of Clinical Oncology.

A Phase I and Pharmacokinetic Study of the Mitochondrial-specific Rhodacyanine Dye Analog MKT 0771

G. Weiss, C. Britten, L. Smith, 2000 .

Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors.

G. Wilding, E. Rowinsky, L. Wood, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia

R. Donehower, W. Slichenmyer, E. Rowinsky, 1995, Cancer Chemotherapy and Pharmacology.

30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors

A. Tolcher, M. Mita, E. Rowinsky, 2004 .

Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks (wks) in patients (pts) with solid tumors

A. Tolcher, C. Takimoto, M. Mita, 2007 .

A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis

C. Higano, P. LoRusso, E. Rowinsky, 2007 .

HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab.

E. Rowinsky, Leah N. Dimascio, Guan Siyu, 2021 .

Regulation of c-Raf-1: therapeutic implications.

M. Beeram, A. Patnaik, E. Rowinsky, 2003, Clinical advances in hematology & oncology : H&O.

Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma

C. Blanke, J. Picus, E. Rowinsky, 2000, Cancer.

Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers.

C. Takimoto, P. LoRusso, M. Beeram, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.

D. V. Von Hoff, S. Baker, M. Villalona-Calero, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Therapy: Clinical Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

M. Hidalgo, M. Mita, A. Mita, 2009 .

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies.

A. Tolcher, M. Mita, C. Bedrosian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

A. Tolcher, J. Verweij, K. Papadopoulos, 2011, British Journal of Cancer.

Phase I a nd P harmacologic S tudy o f P N401 a nd F luorouracil in P atients W ith A dvanced S olid M alignancies

M. Hidalgo, G. Weiss, M. Villalona-Calero, 2000 .

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.

A. Tolcher, A. Patnaik, M. Mita, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging.

A. Tolcher, G. Weiss, M. Beeram, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697)

T. Choueiri, G. Hudes, W. Stadler, 2009 .

Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial.

A. Patnaik, E. Rowinsky, T. Dragovich, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract B001: A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies

S. Tavazoie, M. Postow, M. Mita, 2018 .

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

C. Britten, A. Patnaik, L. Siu, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589A: A novel histone deacetylase inhibitor

P. Atadja, A. Patnaik, M. Mita, 2004 .

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

E. Rowinsky, H. Youssoufian, G. Shah, 2010, Cancer.

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.

G. Demetri, G. Gordon, E. Rowinsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS)

G. Demetri, E. Rowinsky, L. Baker, 2005 .

L. Grochow, D. Ettinger, R. Donehower, 1994, Cancer research.

A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti- epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and oxaliplatin (mFOLFOX-6) as first- line therapy

J. Tabernero, E. Rowinsky, H. Youssoufian, 2008 .

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.

M. Villalona-Calero, E. Rowinsky, R. Drengler, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal administration of Taxol in the management of ovarian cancer.

R. Barakat, J. Lewis, E. Rowinsky, 1993, Journal of the National Cancer Institute. Monographs.

Phase (Ph) I evaluation of the dolastatin analogue synthadotin (SYN-D; ILX651): Pooled data analysis of three alternate schedules in patients (pts) with advanced solid tumors.

E. Hersh, A. Mita, E. Rowinsky, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

409 AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients with refractory or advanced malignancies — a phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study

A. Tolcher, M. Mita, C. Bedrosian, 2004 .